Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time is a research paper published in Neuro-Oncology Advances (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01 NS117432
National Institutes of Health
Grant: U54 CA210180
National Center for Advancing Translational Sciences
Grant: UL1 TR002377
NCI NIH HHS
Grant: T32 CA217836
National Institutes of Health
Grant: 1U54CA210180-01
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors
National Institutes of Health
Grant: 1R01NS117432-01
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming
National Institutes of Health
Grant: 3UL1TR002377-04S5
Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Regan Theiler)
FWCI
0.65
Citation Percentile
0.6%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals